×

Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

  • US 7,829,086 B2
  • Filed: 03/06/2007
  • Issued: 11/09/2010
  • Est. Priority Date: 03/06/2006
  • Status: Expired due to Fees
First Claim
Patent Images

1. A monoclonal humanized anti-CD22 antibody comprising a heavy chain and a light chain, wherein the heavy chain variable region (“

  • VH”

    ) comprises three complementarity determining regions, VH CDR1, VH CDR2, and VH CDR3, and four framework regions, VH FW1, VH FW2, VH FW3, and VH FW4, in the order VH FW1-VH CDR1-VH FW2-VH CDR2-VH FW3-VH CDR3-VH FW4;

    wherein VH CDR1 comprises the amino acid sequence DYGVN (SEQ ID NO;

    62), VH CDR2 comprises the amino acid sequence IIWGDGRTDYNSALKS (SEQ ID NO;

    63), and VH CDR3 comprises the amino acid sequence APGNRAMEY (SEQ ID NO;

    64);

    wherein the light chain variable region (“

    VK”

    ) comprises three complementarity determining regions, VK CDR1, VK CDR2, and VK CDR3, wherein VK CDR1 comprises the amino acid sequence KASQSVTNDVA (SEQ ID NO;

    65), VK CDR2 comprises the amino acid sequence YASNRYT (SEQ ID NO;

    66), and VK CDR3 comprises the amino acid sequence QQDYRSPWT (SEQ ID NO;

    67), andwherein VH FW1 comprises the amino acid sequence QVQLEESGGGVVRPGRSLRLSCAASGFTFS (SEQ ID NO;

    81).

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×